Browse through our press and news section by category:

05.02.2020, Mainz, Germany

SCHOTT extends syriQ BioPure® syringe format to enable optimized administration

The new 2.25mL long syringe was developed for highly viscous biologics, which are administered by use of an autoinjector.

syriQ BioPure® syringes are specifically designed to keep sensitive biologic drugs stable over their shelf life while easing the administration process for patients. The portfolio now includes a new 2.25mL syringe format, which supports both the drug’s and patient’s needs when it comes to administering highly viscous biologics by autoinjector. The new container format will be introduced at Pharmapack trade show in Paris, February 5-6, where SCHOTT is presenting its full range of pharmaceutical containers at booth D60.

The new 2.25mL syriQ BioPure^® syringe was developed for highly viscous biologics, which are administered by use of an autoinjector. Image: SCHOTT

Biologic drugs provide treatment options for hard-to-treat diseases, yet administering these drugs comes with some challenges. One of these is that the bioavailability is increased in order to ensure the efficiency of the treatments, which leads to a higher Active Pharmaceutical Ingredient (API) concentration. This results in an increased drug viscosity, which means that more force is required to inject the drug. However, if too much force is applied, the injection process becomes uncomfortable for the patient and the syringe may break. Another aspect is that the high concentration of complex and large molecules can interact with the container and cause stability issues.

To solve these challenges, SCHOTT is introducing syriQ BioPure^® in a 2.25mL format for use in autoinjectors. “The standard 1mL long glass syringe is too small in volume for the increase in bioavailability, yet a container beyond 3mL would be too big for administration,” explains Anil Kumar Busimi, Senior Global Product Manager for the SCHOTT iQ^® Platform at SCHOTT. “The new 2.25mL long syringes therefore ensure the efficiency of the treatment, while also making the administration with an autoinjector easier and more comfortable for the patient.”

Enhancing drug stability and device compatibility

As part of the SCHOTT iQ^® platform, all syriQ BioPure^® syringes are delivered pre-sterilized in a standard nest and tub. The syringes are manufactured under improved processes to lower tungsten and adhesive residuals, and the use of high-end materials further result in a superior E&L profile (Extractables & Leachables) to ensure drug stability. Moreover, accurate dimensions ensure optimal device compatibility, meeting market demand for products that can be administered at home for patient comfort.

About SCHOTT
SCHOTT is a leading international technology group in the areas of specialty glass, glass-ceramics and related high-tech materials. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT has a global presence with production sites and sales offices in 34 countries. In the 2018/2019 fiscal year, the group generated sales of EUR 2.2 billion with over 16,200 employees. SCHOTT AG has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. This is one of the oldest private and largest science-promoting foundations in Germany. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.

Press contact:
Joana Kornblum
E-mail: joana.kornblum@schott.com
Phone: +49 6131 66 4073